JP2014517078A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517078A5
JP2014517078A5 JP2014517231A JP2014517231A JP2014517078A5 JP 2014517078 A5 JP2014517078 A5 JP 2014517078A5 JP 2014517231 A JP2014517231 A JP 2014517231A JP 2014517231 A JP2014517231 A JP 2014517231A JP 2014517078 A5 JP2014517078 A5 JP 2014517078A5
Authority
JP
Japan
Prior art keywords
compound
disorder
pharmaceutical composition
composition according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517231A
Other languages
English (en)
Japanese (ja)
Other versions
JP6087911B2 (ja
JP2014517078A (ja
Filing date
Publication date
Priority claimed from PCT/US2011/041866 external-priority patent/WO2012177263A1/en
Application filed filed Critical
Publication of JP2014517078A publication Critical patent/JP2014517078A/ja
Publication of JP2014517078A5 publication Critical patent/JP2014517078A5/ja
Application granted granted Critical
Publication of JP6087911B2 publication Critical patent/JP6087911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517231A 2011-06-24 2012-06-22 有機化合物 Active JP6087911B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
USPCT/US2011/041866 2011-06-24
PCT/US2011/041866 WO2012177263A1 (en) 2011-06-24 2011-06-24 Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US201161501207P 2011-06-25 2011-06-25
US61/501,207 2011-06-25
PCT/US2012/043880 WO2012178112A1 (en) 2011-06-24 2012-06-22 Organic compounds

Publications (3)

Publication Number Publication Date
JP2014517078A JP2014517078A (ja) 2014-07-17
JP2014517078A5 true JP2014517078A5 (enExample) 2015-10-01
JP6087911B2 JP6087911B2 (ja) 2017-03-01

Family

ID=47422974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517231A Active JP6087911B2 (ja) 2011-06-24 2012-06-22 有機化合物

Country Status (13)

Country Link
US (4) US9469625B2 (enExample)
EP (1) EP2723173B1 (enExample)
JP (1) JP6087911B2 (enExample)
KR (1) KR20140036305A (enExample)
CN (1) CN103717069B (enExample)
AU (2) AU2012272680A1 (enExample)
BR (1) BR112013033306A2 (enExample)
CA (2) CA2840047A1 (enExample)
ES (1) ES2627338T3 (enExample)
IL (1) IL230036A (enExample)
MX (1) MX342322B (enExample)
RU (1) RU2610094C2 (enExample)
WO (3) WO2012177263A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US11491150B2 (en) 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2019152680A1 (en) * 2018-01-31 2019-08-08 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using chrna6 inhibitors
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
WO2021008565A1 (zh) * 2019-07-16 2021-01-21 清华大学 乙酰胆碱通路调节剂在治疗癌症中的用途
EP4238970A1 (en) * 2022-03-03 2023-09-06 InterAx Biotech AG Modulators of ackr3 and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
ES2338539T3 (es) * 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
BR0315056A (pt) 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
MXPA05007689A (es) * 2003-01-22 2005-09-30 Pharmacia & Upjohn Co Llc Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach.
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2006525355A (ja) * 2003-05-01 2006-11-09 アボット・ラボラトリーズ ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
WO2009112459A1 (en) 2008-03-11 2009-09-17 Neurosearch A/S Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
US20100179186A1 (en) 2008-10-10 2010-07-15 University Of Kentucky Research Foundation USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists

Similar Documents

Publication Publication Date Title
JP2014517078A5 (enExample)
JP2014500295A5 (enExample)
JP2014517050A5 (enExample)
JP2017528487A5 (enExample)
AU2014220377B2 (en) Treatment of graft versus host disease in transplant patients
JP2019515908A5 (enExample)
JP2014513705A (ja) 進行性固形腫瘍の治療方法
RU2014102191A (ru) Органические соединения
CN110198716A (zh) 癌症治疗
RU2020108192A (ru) Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf
JP2021113228A (ja) 重度腎機能障害を有する癌患者に対する治療方法
CN106632383A (zh) 莪术醇衍生物及其制备方法和在抗肿瘤药物中的应用
JP2018525447A5 (enExample)
de Rouw et al. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis
WO2025167738A1 (zh) 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用
US9376432B2 (en) Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma
Kizior et al. Saunders Nursing Drug Handbook 2026-E-Book
Yu et al. OA03. 04 efficacy and safety of the novel HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
JP2018506534A5 (enExample)
JP2020530851A5 (enExample)
Nakamura et al. OA03. 05 Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Park et al. C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines.
Jones Chloroquine and quinine
HK40096869A (zh) 结晶5-(二甲基氨基)-n-(4-(吗啉代甲基)苯基)萘-1-磺酰胺二盐酸盐二水合物
JP2013544844A5 (enExample)